Search
Moleculin Biotech Inc
MBRXAdd to Watchlist
2.640USD
-0.050-1.86%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.09MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.86%
5 Days
-19.27%
1 Month
+5.18%
6 Months
-27.07%
Year to Date
-20.24%
1 Year
-68.94%
Key Figures
2.570Open
2.780High
361.59KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
6.78%Turnover Ratio
2.690Prev. Close
2.556Low
607.88KTurnover
LossP/E Static
0.93P/B
0.00%Div Yield TTM
-182.54%ROA
24.00052wk High
0.43Volume Ratio
-21.76MNet Profit
5.34MShares
-16.1644EPS TTM
1.76Beta
-556.58%ROE
1.79052wk Low
8.33%Amplitude
--Gross Margin
14.09MMarket Cap
1.27Reward/Risk
5.65%Risk Rate
TradingKey Stock Score of Moleculin Biotech Inc
Currency: USD Updated: 2026-07-02Key Insights
Moleculin Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Moleculin Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Moleculin Biotech Inc Highlights
StrengthsRisks
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Fairly Valued
The company’s latest PE is -0.16, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 132.10K shares, increasing 19.80% quarter-over-quarter.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
21.000
Target Price
+680.67%
Upside Space
Moleculin Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Moleculin Biotech Inc Info
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Ticker SymbolMBRX
CompanyMoleculin Biotech Inc
CEOKlemp (Walter V)
Websitehttps://moleculin.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Moleculin Biotech Inc (MBRX)?
The current price of Moleculin Biotech Inc (MBRX) is 2.64.
What is the symbol of Moleculin Biotech Inc?
The ticker symbol of Moleculin Biotech Inc is MBRX.
What is the 52-week high of Moleculin Biotech Inc?
The 52-week high of Moleculin Biotech Inc is 24.00.
What is the 52-week low of Moleculin Biotech Inc?
The 52-week low of Moleculin Biotech Inc is 1.79.
What is the market capitalization of Moleculin Biotech Inc?
The market capitalization of Moleculin Biotech Inc is 14.09M.
Is Moleculin Biotech Inc (MBRX) currently rated as Buy, Hold, or Sell?
According to analysts, Moleculin Biotech Inc (MBRX) has an overall rating of Buy, with a price target of 21.00.
What is the Earnings Per Share (EPS TTM) of Moleculin Biotech Inc (MBRX)?
The Earnings Per Share (EPS TTM) of Moleculin Biotech Inc (MBRX) is -28.42.